Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
ConclusionThe 40-GEP test demonstrates accurate, independent, clinically actionable stratification of metastatic risk and improves predictive accuracy when integrated into risk classification systems. The improved accuracy of risk assessment when including tumor biology via the 40-GEP test ensures more risk-aligned, personalized patient management decisions. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 1, 2024 Category: Dermatology Source Type: research
Botulinum Toxin A and B for Palmoplantar Hyperhidrosis
ConclusionWe found that BTX-A and BTX-B treatment for palmar hyperhidrosis and BTX-B treatment for plantar hyperhidrosis led to a substantial improvement of QoL. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 1, 2024 Category: Dermatology Source Type: research
Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients
ConclusionThe 40-GEP test demonstrates accurate, independent, clinically actionable stratification of metastatic risk and improves predictive accuracy when integrated into risk classification systems. The improved accuracy of risk assessment when including tumor biology via the 40-GEP test ensures more risk-aligned, personalized patient management decisions. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - March 1, 2024 Category: Dermatology Source Type: research
Herpes Zoster Recurrence: A Narrative Review of the Literature
DiscussionOur review underlines that following an initial HZ episode, individuals remain at risk of HZ recurrence, adding to the disease burden in a population. As HZ is preventable by vaccination, national HZ vaccination recommendations should include the need for and timing of vaccination in both immunocompetent and immunocompromised individuals who have a history of HZ. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 28, 2024 Category: Dermatology Source Type: research
Insights into Early Systemic Treatment in Atopic Dermatitis: Scientific Facts and Practical Considerations
In conclusion, the safety and efficacy of novel systemic treatments offer a compelling scenario for early intervention in atopic dermatitis care. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 27, 2024 Category: Dermatology Source Type: research
Readability of Patient Electronic Materials for Atopic Dermatitis in 23 Languages: Analysis and Implications for Dermatologists
ConclusionsAlthough there was an abundance of online articles related to AD, the readability of the available information was low. As online health information has become essential in making shared decisions between patients and physicians, an improvement in AD-related materials is needed. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 24, 2024 Category: Dermatology Source Type: research
Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
ConclusionAdministration of the RIPK1 inhibitor GSK2982772 to patients with moderate to severe plaque psoriasis did not translate into meaningful clinical improvements. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 19, 2024 Category: Dermatology Source Type: research
Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’
(Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 16, 2024 Category: Dermatology Source Type: research
Clinical and Disease Burden of Patients with Generalized Pustular Psoriasis: A Review of Real-World Evidence
AbstractGeneralized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening disease. There is limited understanding of patient characteristics in GPP and their correlation with disease progression or healthcare resource utilization. Our review aims to examine real-world evidence on these characteristics and the associated disease burden as related to economic and quality of life factors. Results showed that most patients with GPP experienced flares once a year, lasting from 2 weeks to 3 months, with> 80% of patients having residual disease post-flare, with/without treatment, indicating the long-...
Source: Dermatology and Therapy - February 16, 2024 Category: Dermatology Source Type: research
Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience
ConclusionThese results show that regardless of NIS location, Cal/BD foam remains a well-tolerated, efficacious option for patient care that could be used as a first-line topical therapy for mild-to-severe psoriasis. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - February 15, 2024 Category: Dermatology Source Type: research
